GlassScriptPhysician profile
Dreux R Patton
NPI 1699852384
$15,276.20
in general payments reported to CMS, 2019-2025
54 companies · $2,957 in 2025
The $2,957 reported for 2025 was more than what 95% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,496 · 2020: $1,471 · 2021: $2,355 · 2022: $1,946 · 2023: $2,354 · 2024: $1,697 · 2025: $2,957.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,007.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,007.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $1,833.11 | 2019-2025 | Vyepti |
| Biogen, INC. | $1,398.25 | 2019-2025 | Vumerity, Tysabri, Zurzuvae |
| Abbvie INC. | $1,112.71 | 2019-2025 | |
| Argenx US, INC. | $1,019.29 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Harmony Biosciences LLC | $973.80 | 2020-2025 | Wakix |
| Alexion Pharmaceuticals, INC. | $963.45 | 2019-2025 | Soliris, Ultomiris |
| Amneal Pharmaceuticals LLC | $775.47 | 2024-2025 | Crexont, Ongentys, Rytary |
| Amgen INC. | $736.45 | 2019-2025 | Uplizna, Evenity |
| Teva Pharmaceuticals USA, INC. | $735.43 | 2019-2021 | |
| Emd Serono, INC. | $598.27 | 2019-2024 | Mavenclad, Mavenclad |
| Supernus Pharmaceuticals, INC. | $341.56 | 2019-2022 | |
| Sk Life Science, INC. | $340.20 | 2022 | |
| Axsome Therapeutics, INC. | $298.36 | 2025 | Symbravo |
| Ucb, INC. | $291.28 | 2023-2024 | Rystiggo, Briviact |
| Hologic Sales and Service, LLC | $277.35 | 2019-2023 | Thinprep 2000 Processor |
Show all 53 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dreux Patton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.